PROCEPT BioRobotics (PRCT) Competitors $62.25 -3.14 (-4.80%) Closing price 04:00 PM EasternExtended Trading$62.74 +0.49 (+0.80%) As of 07:38 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends PRCT vs. SOLV, SNN, PEN, GKOS, STVN, BLCO, INSP, NARI, NVST, and IRTCShould you be buying PROCEPT BioRobotics stock or one of its competitors? The main competitors of PROCEPT BioRobotics include Solventum (SOLV), Smith & Nephew (SNN), Penumbra (PEN), Glaukos (GKOS), Stevanato Group (STVN), Bausch + Lomb (BLCO), Inspire Medical Systems (INSP), Inari Medical (NARI), Envista (NVST), and iRhythm Technologies (IRTC). These companies are all part of the "medical equipment" industry. PROCEPT BioRobotics vs. Solventum Smith & Nephew Penumbra Glaukos Stevanato Group Bausch + Lomb Inspire Medical Systems Inari Medical Envista iRhythm Technologies PROCEPT BioRobotics (NASDAQ:PRCT) and Solventum (NYSE:SOLV) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their dividends, analyst recommendations, risk, media sentiment, profitability, institutional ownership, community ranking, valuation and earnings. Do insiders & institutionals believe in PRCT or SOLV? 89.5% of PROCEPT BioRobotics shares are owned by institutional investors. 17.4% of PROCEPT BioRobotics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term. Which has higher earnings and valuation, PRCT or SOLV? Solventum has lower revenue, but higher earnings than PROCEPT BioRobotics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioPROCEPT BioRobotics$136.19M23.85-$105.90M-$1.95-31.92SolventumN/AN/AN/AN/AN/A Is PRCT or SOLV more profitable? Solventum has a net margin of 0.00% compared to PROCEPT BioRobotics' net margin of -50.07%. Solventum's return on equity of 0.00% beat PROCEPT BioRobotics' return on equity.Company Net Margins Return on Equity Return on Assets PROCEPT BioRobotics-50.07% -38.57% -26.06% Solventum N/A N/A N/A Do analysts recommend PRCT or SOLV? PROCEPT BioRobotics presently has a consensus target price of $97.86, indicating a potential upside of 57.20%. Solventum has a consensus target price of $68.29, indicating a potential downside of 6.56%. Given PROCEPT BioRobotics' stronger consensus rating and higher possible upside, research analysts clearly believe PROCEPT BioRobotics is more favorable than Solventum.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score PROCEPT BioRobotics 0 Sell rating(s) 1 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 2.86Solventum 1 Sell rating(s) 9 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Does the MarketBeat Community favor PRCT or SOLV? PROCEPT BioRobotics received 37 more outperform votes than Solventum when rated by MarketBeat users. Likewise, 67.86% of users gave PROCEPT BioRobotics an outperform vote while only 5.56% of users gave Solventum an outperform vote. CompanyUnderperformOutperformPROCEPT BioRoboticsOutperform Votes3867.86% Underperform Votes1832.14% SolventumOutperform Votes15.56%Underperform Votes1794.44% Does the media favor PRCT or SOLV? In the previous week, Solventum had 4 more articles in the media than PROCEPT BioRobotics. MarketBeat recorded 9 mentions for Solventum and 5 mentions for PROCEPT BioRobotics. PROCEPT BioRobotics' average media sentiment score of 1.36 beat Solventum's score of 0.95 indicating that PROCEPT BioRobotics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment PROCEPT BioRobotics 4 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Solventum 6 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive SummaryPROCEPT BioRobotics beats Solventum on 9 of the 13 factors compared between the two stocks. Get PROCEPT BioRobotics News Delivered to You Automatically Sign up to receive the latest news and ratings for PRCT and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart PRCT vs. The Competition Export to ExcelMetricPROCEPT BioRoboticsSurgical & medical instruments IndustryMedical SectorNASDAQ ExchangeMarket Cap$3.25B$4.59B$5.78B$8.98BDividend YieldN/A39.91%4.78%3.85%P/E Ratio-31.9231.4526.4618.82Price / Sales23.8550.79457.6880.73Price / CashN/A51.2344.0437.47Price / Book11.206.577.634.64Net Income-$105.90M$90.13M$3.18B$245.69M7 Day Performance-7.93%-2.45%-1.82%-2.63%1 Month Performance-10.75%-2.38%0.22%-2.37%1 Year Performance28.27%14.92%17.49%13.65% PROCEPT BioRobotics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)PRCTPROCEPT BioRobotics3.2681 of 5 stars$62.25-4.8%$97.86+57.2%+33.5%$3.25B$136.19M-31.92430Positive NewsSOLVSolventum0.399 of 5 stars$74.04-0.4%$68.29-7.8%N/A$12.79BN/A0.0022,000Upcoming EarningsSNNSmith & Nephew2.483 of 5 stars$25.72+0.0%N/A-9.8%$11.24B$5.55B0.0018,452Upcoming EarningsPENPenumbra4.459 of 5 stars$267.83-1.9%$261.36-2.4%+12.7%$10.28B$1.06B311.434,200Earnings ReportAnalyst ForecastAnalyst RevisionNews CoverageGKOSGlaukos4.399 of 5 stars$153.06+4.6%$151.08-1.3%+71.4%$8.44B$314.71M-50.68780Earnings ReportAnalyst UpgradeInsider TradeNews CoverageGap DownSTVNStevanato Group1.236 of 5 stars€19.49+2.2%N/A-32.5%$5.90B$1.17B41.475,635Positive NewsBLCOBausch + Lomb3.7366 of 5 stars$16.44-1.2%$20.25+23.2%+9.1%$5.79B$4.15B-15.6513,300Earnings ReportAnalyst ForecastAnalyst RevisionNews CoverageINSPInspire Medical Systems4.8316 of 5 stars$184.73-1.3%$228.82+23.9%-7.0%$5.54B$624.80M172.651,011Insider TradeNARIInari Medical1.6759 of 5 stars$79.93flat$68.00-14.9%+37.6%$4.68B$493.63M-59.211,300NVSTEnvista3.5382 of 5 stars$21.59+0.3%$20.21-6.4%-6.5%$3.71B$2.51B-3.3312,800IRTCiRhythm Technologies1.0045 of 5 stars$112.11-0.1%$108.45-3.3%+0.2%$3.51B$492.68M-23.072,000Earnings ReportAnalyst ForecastNews CoverageGap Up Related Companies and Tools Related Companies SOLV Competitors SNN Competitors PEN Competitors GKOS Competitors STVN Competitors BLCO Competitors INSP Competitors NARI Competitors NVST Competitors IRTC Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:PRCT) was last updated on 2/21/2025 by MarketBeat.com Staff From Our PartnersCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredElon “obliterates” Bill Gates?All 10 of the world's biggest money managers follow my work, and the Pentagon, the FBI and Harvard professors ...Altimetry | SponsoredNVDA Crash UpdateAn overseas AI rival sent shockwaves through the U.S. tech market last week... Leaving millions of investor...Chaikin Analytics | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | Sponsored Is Starlink Set For The Largest IPO In History?He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it again ...Paradigm Press | Sponsored My 2025 AI BlueprintI first recommended Bitcoin at $300 in 2013 … before it went up 33,645%. Now, I am revealing my 2025 AI Blu...Weiss Ratings | SponsoredBuy this AI Stock Before Elon’s AnnouncementWith Trump back in office, xAI is primed to become the leader in generative AI, leaving competitors in the dus...InvestorPlace | SponsoredAmerica cannot power AIThere’s a fatal flaw at the heart of the AI revolution… With AI continuing to explode in popularity, tech c...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding PROCEPT BioRobotics Co. Please log in to your account or sign up in order to add this asset to your watchlist. Share PROCEPT BioRobotics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
